Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof ‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial
ConclusionsThe HOMAGE trial will provide insights on the effect of spironolactone on pathways that might drive progression to HF.Clinical Trial Registration: ClinicalTrials.gov NCT02556450.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Pierpaolo Pellicori,
Jo ão Pedro Ferreira,
Beatrice Mariottoni,
Hans‐Peter Brunner‐La Rocca,
Fozia Z. Ahmed,
Job Verdonschot,
Tim Collier,
Joe J. Cuthbert,
Johannes Petutschnigg,
Blerim Mujaj,
Nicolas Girerd,
Arantxa González,
Andrew L. Tags: Study Design Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Hypertension | Spironolactone | Study | Women